Intermittent androgen deprivation in advanced prostate cancer

Urological Research

Volumn 25, Issue SUPPL. 2, 1997, Pages

  De Reijke, T M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; GONADORELIN DERIVATIVE;

ADVANCED CANCER; CANCER THERAPY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030923927     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf00941990     Document Type: Review

References (35)

1. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD (1993) Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer 71:2782
2. Bales GT, Sinner MD, Kim JH, Chodak GW (1996) Impact of intermittent androgen deprivation on quality of life (QOL). J Urol 155:578A
3. Benson MC, Vries G de, Katz AE, Olsson CA, Buttyan RE (1996) Enhanced RT-PCR for PSA offers unique prognostic information during androgen deprivation therapy. J Urol 155: 437A
4. Bissada NK, Kaczmarek AT (1995) Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. J Urol 153:1944
5. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D (1990) Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50:2275
6. Crawford ED (1992) Challenges in the management of prostate cancer. Br J Urol [Suppl] 70:33
7. Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA (1996) Serum prostate specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 47:863
8. Cunha GR, Donjacour AA, Cooke PS (1987) The endocrinology and development biology of the prostate. Endocr Rev 8:338
9. Dawson NA, McLeod DG (1995) Dramatic prostate-specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 153:1946
10. DeAntoni E, Crawford ED, Stone EE, Blum DS, Berger ER, Eisenberger MA, Gambert SR, Staggers F (1993) Prostate Cancer Awareness Week, 1992: a summary of key findings. Clin Invest Med 16:448
11. Denis L (1993) Prostate cancer: primary hormonal treatment. Cancer 71:1050
12. Gleave M, Bruchovsky N, Bowden M, Goldenberg L. Sullivan LD (1994) Intermittent androgen suppression prolongs time to androgen-independent progression in the LNCaP prostate tumor model. J Urol 151:457A
13. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K (1995) Intermittent androgen suppression in the treatment of prostate cancer A preliminary report. Urology 45.839
14. Griffiths K, Coffey D, Cockett A, Di Sant Agnese A, Ichikawa T, Krieg H, Lee C, McKeehan N, Schalken J, Sciarra J, Steiner G, Sugimura Y, Yamanaka H (1995) 3rd international consultation on benign prostatic hyperplasia. proceedings. Scientific Communication International Jersey, p 73
15. Jacobsen SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, Chute CG, Lieber MM (1995) Incidence of prostate cancer diagnosis in the eras before and after prostate-specific antigen testing. JAMA 274:1445
16. Klotz LH, Herr HW, Morse MJ, Whitmore WF (1986) Intermittent endocrine therapy for advanced prostate cancer. Cancer 58:2546
17. Leo ME, Bilhartz DL, Bergstralh EJ, Oesterling JE (1991) Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol 145:802
18. Lepor H, Ross A, Walsh PC (1982) The influence of hormonal therapy on survival of men with advanced prostate cancer. J Urol 128:335
19. Lu-Yao GL, Greenberg ER (1994) Changes in prostate cancer incidence and treatment in the USA. Lancet 343:251
20. Matzkin H, Eber P, Todd B, Zwaag R vd, Soloway MS (1992) Prognostic significance of changes in prostate specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer 70:2302
21. McDonnel T, Eschenbach A von, Marin M, Fernandez A, Westin P, Tu S-M, Brisbay S, Bick R, Buja LM, McConkey D (1996) bcl-2 confers resistance to cell death induction by androgen-ablation and chemotherapy in prostate cancer cells. J Urol 155:527A
22. Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR (1992) The clinical usefulness of serum prostate-specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147:956
23. Moller-Jensen O, Estève J, Moller H, Renard H (1990) Cancer in the european community and its member states. Eur J Cancer 26:1167
24. Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE, Crook J, Gulenchyn KY, Hong KE, Wesolowski C, Yardley J (1993) Result of a randomized Phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiation Oncology Biol Phys 25:805
25. Resnick MI (1984) Hormonal therapy in prostatic carcinoma. Urology 24:18
26. Russo P, Liquori G, Heston DW, Huryk R, Yang CR, Fair WR, Whitmore WF, Herr HW (1987) Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma. Cancer Res 47:5967
27. Santucci RA, Ellis WJ, Buhler KR, Daniel J, Lange PH, Vessella RL (1996) Intermittent androgen suppression for advanced prostate cancer a xenograft model. J Urol 155:510A
28. Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566
29. Scher HI. Fossa S (1995) Prostate cancer in the era of prostate-specific antigen. Curr Opin Urol 7:281
30. Small EJ. Carroll PR (1994) Prostate-specific androgen decline after Casodex withdrawal: evidence for an antiandrogen with-drawal syndrome. Urology 43:408
31. Small EJ, Srinivas S (1995) The antiandrogen withdrawal syndrome. Cancer 76:1428
32. Soloway MS (1990) The importance of prognostic factors in advanced prostate cancer. Cancer 66:1017
33. Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP (1995) Mutation of the androaen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393
34. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E (1992) Anti-androgen and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat shock protein interaction and transcription activation. Biochemistry 31:2393
35. Voogt HJ de, Suciu S, Sylvester R, Pavone-Macaluso M, Smith PH, Pauw M de and members of the European Organization for Research on treatment of cancer genitourinary tract cancer cooperative group (1989) Multivariate analysis of prognostic factors in patients with advanced prostatic cancer, results from 2 European Organization for Research on treatment of cancer trials. J Urol 141:883